Wall Street Researcher
PetVivo Holdings Inc
PETV NASDAQ
Watch Latest CEO Interview
Target Price $7.00 By Think Equity Research Report
Earnings And Business Update Call Transcript
PetVivo Reports First Quarter of Fiscal 2023 Financial Results
Recent Insider Buying Director
Recent Insider Buying Director
Recent Insider Buying Director
Recent Insider Buying Director
From 6-30-22 to 7-7-22 over 60,000 shares were acquired by three insiders ranging in price from $1.27 to $1.79 We feel that this is a significant indicator of the future value of PETV shares. Insider buying, especially in a weak market environment is a signal of a bright future ahead for the company.
Recently these shares spiked above $2.60 before settling back to current levels, all on news of a major distribution agreement with a top Veterinary Supply and Services Company. ( See Press Release Below )
__________________________________________
These shares are ready to BREAKOUT above its 200 day moving average of $2.37 . With a yearly high of $8.80 we expect PETV shares to continue to advance on upcoming news on developing products and patents .The company has 19 patents with a pipeline of 17 products.
We urge all serious investors to place these shares immediately on their BUY LIST.
PetVivo Holdings, Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently-regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products containing propriety thermoplastic protein based biomaterials that mimic the bodys tissue. a portfolio of 19 patents and 8 pending patent applications protects the companys biomaterials, products, production process and methods of use.
WEBSITE MANAGEMENT RESEARCH REPORT CEO INTERVIEW
PetVivo Reports First Quarter of Fiscal 2023 Financial Results
EDINA, MN, Aug. 11, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (PETV-OLD) (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the first quarter of fiscal 2023.
Highlights from the first quarter of 2023 and recent weeks include the following (all comparisons are with the first quarter of 2022, unless otherwise indicated):
- Entered into a Distribution and Sales Agreement with MWI Animal Health, a leading distributor of animal health products on June 17, 2022
- Revenues of $58,174 in the first quarter of fiscal 2023, compared to revenues of $4,145 in the first quarter of fiscal 2022
Management Commentary
John Lai, CEO, commented, “I am happy to report that our investment in sales and marketing for our Spryng™ veterinarian device, with OsteoCushion Technology™ is beginning to yield positive results for us. We have now opened up accounts with veterinary clinics in 37 states.
I am also excited about the exclusive Distribution and Sales Agreement with MWI Animal Health (“MWI”), a leading distributor of animal health products and subsidiary of AmeriSource Bergen, which we entered into in June 2022. We view MWI as a strategic partner that will allow our company significant exposure to and penetration into the US animal health market. MWI has a network of distribution centers in key markets nationwide and over 400 territory managers. This new relationship will benefit the industry, the veterinarians who provide medical care, their patients, and pet owners alike.”
First Quarter Financial Results
Revenues. Revenue was $58,174 and $4,145 for three months ended June 30, 2022 and 2021, respectively, and consisted of Spryng™ sales to veterinary clinics. The Company began commercialization of its Spryng™ product in September 2021, which resulted in increased revenues in the three months ended June 30, 2022 compared to the same period in the prior year.
Cost of Sales. Cost of sales was $53,020 and $5,051 for the three months ended June 30, 2022 and 2021, respectively. Cost of sales includes product costs related to the sale of products and labor and overhead costs. The Company began commercialization of its Spryng™ product in September 2021, which resulted in increased costs of sales in the three months ended June 30, 2022 compared to the same period in the prior year.
Operating Expenses. Operating expenses were $1,917,247 and $517,613 for the three months ended June 30, 2022 and 2021, respectively. Operating expenses consisted of general and administrative, sales and marketing, and research and development expenses. The Company began commercialization of its Spryng™ product in September 2021, which resulted in increased general and administrative expenses and sales and marketing expenses related to the sale of its Spryng™ product in the three months ended June 30, 2022 compared to the same period in the prior year.
Operating Loss. As a result of the foregoing, our operating loss was $1,966,093 and $518,519 for the three months ended June 30, 2022 and 2021, respectively. The increase in our operating loss was related to the costs to support the launch of Spryng™ and the incremental public company costs incurred in the three months ended June 30, 2022 compared to the same period in the prior year.
Other Income. Other income was $665 for the three months ended June 30, 2022 as compared to other income of $27,890 for the three months ended June 30, 2021. Other income in 2022 consisted of net interest income. Other income in 2021 consisted of the forgiveness of PPP Loan and accrued interest of $31,680 partially offset by interest expense of $3,790.
Net Loss. Our net loss for the three months ended June 30, 2022 was $1,965,428 or ($0.20) per share as compared to a net loss of $490,629 or ($0.07) per share for the three months ended June 30, 2021. The increase in our net loss was related to the costs to support the launch of Spryng™ and the incremental public company costs incurred in the three months ended June 30, 2022 compared to the same period in the prior year. The weighted average number of shares outstanding was 9,988,361 compared to 6,946,353 for the three months ended June 30, 2022 and 2021, respectively.
Balance Sheet and Inventory
At June 30, 2022, the Company had $4.4 million in cash and working capital of $3.8 million. The Company increased its inventory to $180,874 as of June 30, 2022 in order to support its expected revenue growth in 2023.
PetVivo Holdings, Inc. Announces Formation of Nonprofit PetVivo Cares To Advance The Health & Well-Being of Companion Animals
MINNEAPOLIS, July 19, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (“PetVivo”), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for pets, is pleased to announce the launch of a philanthropic endeavor called PetVivo Cares, a registered 501(c)(3) organization.
PetVivo Cares is partnering with the animal healthcare community to advance the health and well-being of animals experiencing discomfort from lameness or other joint related afflictions, such as osteoarthritis. “We take our goals seriously,” said Scott Herold, Executive Director of PetVivo Cares. “Our mission is to provide animal-based nonprofits & companion/therapy animal organizations, with no-cost or reduced-cost Spryng ™ with OsteoCushion™ Technology. PetVivo Cares is dedicated to providing the best quality of life for your pets so that you can focus on loving and enjoying your companion animal.”
PetVivo and PetVivo Cares have a genuine passion for animals. To demonstrate this passion, PetVivo has set a goal to donate 500 no-cost Spryng injections to animal organizations. Spryng, an injectable veterinary medical device administered by licensed veterinarians, will be provided on a financial or critical needs basis. With the support of private donations, PetVivo Cares can grow the success stories exponentially, expanding the PetVivo’s reach to treat even more dogs, cats, horses and other animals suffering from lameness and other joint related afflictions.
“We are very excited to be able to give back to the animal care community, via its numerous and dedicated organizations,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We’ve gotten to know so many wonderful animals as well as people, and we are excited to discover how we can further help animals experiencing joint discomfort. Nothing is better than seeing an animal recover and spring back into action after treatment.”
Leading PetVivo Cares as Executive Director is Scott Herold, multi-award-winning philanthropist, youth advocate, and nonprofit record label executive. Herold is a seasoned veteran of the nonprofit world and his work with Rock the Cause Records and High School for Recording Arts is well respected in philanthropic circles. “Much of my work has been focused on arts and underserved youth. I am looking forward to discovering new ways of serving our community through its beloved animal friends,” said Mr. Herold.
Designed by Stickerbook Collective, PetVivo Cares is launching a dynamic new website in celebration of its pet wellness strides. The PetVivo Cares website will feature the personal triumphs of each pet receiving Spryng with individual blog posts to track their journeys to joint recovery. In addition to TikTok and Instagram reels, PetVivo Cares will be featuring blog posts on Pinterest, so you can meet the charming personalities of our clients. To find out more about our revolutionary product or to see if your organization qualifies for a PetVivo Cares Spryng grant visit petvivocares.org or call 1-888-478-8273. You can also follow us @petvivocares on all social platforms.
Spryng is only sold in the United States and its territories. For more information about Spryng also visit the technology page on petvivocares.org .
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG ™ with OsteoCushion ™ technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit https://petvivo.com/
About PetVivo Cares, Inc.
PetVivo Cares is a nonprofit community-focused organization dedicated to advancing the health and well-being of companion animals. We partner with the animal health community to provide reduced-cost or no-cost SPRYNG ™ with Osteo-Cushion Technology, a product developed by PetVivo, Inc. (“PetVivo”). SPRYNG ™ is an effective tool to aid in the management of osteoarthritis, lameness, and rehabilitation of companion animals.
PetVivo Cares wants to enhance the lives of companion animals by helping to make SPRYNG ™ available to animals who may not have the opportunity to receive it. Discover PetVivo Cares at petvivocares.org or follow our socials @petvivocare
PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION SERVICES AGREEMENT WITH MWI ANIMAL HEALTH
MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (“PetVivo”), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine athletes and companion animals, announced today it has entered into a definitive exclusive distribution services agreement with MWI Animal Health, a leading distributor of animal health products and services and a subsidiary of AmerisourceBergen.
MWI will inventory, market, and promote PetVivo’s veterinary medical device, Spryng ™ with OsteoCushion ™ Technology, throughout the United States. Through its network of distribution centers in key markets nationwide, MWI can support efficient deliveries to communities nationwide.
“We are pleased with the commitment MWI has made to PetVivo in the roll out of this new relationship that includes the distribution of our lead product, Spryng. We view MWI as a strategic partner that will allow PetVivo significant exposure to and penetration in the US animal health market. This new relationship will benefit the industry, the veterinarian who provides the medical care, their patients and the pet owner alike,” stated John Lai, Chief Executive Officer for PetVivo.
PetVivo’s innovative product, Spryng with OsteoCushion Technology, is a veterinary medical device comprised of millions of micronized hydrogel matrices, which are derived from natural biocompatible components. OsteoCushion Technology provides both reinforcing natural joint support to augment and reinforce missing and/or damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic administration.
“We continue to see tremendous innovation across the animal health industry, including the emergence of novel therapies and devices. We work closely with companies leading these efforts to ensure veterinarians nationwide have access to the latest products and services that have the potential to help pets live longer and healthier lives,” said Steve Shell, president of MWI Animal Health. “We are thrilled to work with PetVivo to provide veterinarians with timely and reliable access to the company’s new medical device.”
Leslie Coolidge and Rob Costantino Join PetVivo Holdings, Inc. Board of Directors
MINNEAPOLIS, MN, US, Aug. 01, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Rob Costantino and Leslie Coolidge have joined the Company’s Board of Directors.
“We are thrilled to welcome Rob and Leslie to PetVivo’s Board of Directors” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Rob and Leslie bring a wealth of business and governance experience to our Company. We anticipate that their addition to the board will provide us the knowledge and expertise that will guide our Company to attain the resources and industry relationships necessary for success.”
Mr. Costantino is a retired CPA and former senior executive who has served as Chief Executive Officer, Chief Operating Officer and Chief Financial Officer of large corporations. He is currently a part time financial consultant, investor and a current member of the Board of Directors of 4 Yamaha Motor Finance subsidiaries. His most recent executive position was a dual role of Senior Executive Vice President – Chief Financial Officer and Chief Operating Officer of NASDAQ listed WFS Financial, Inc., an automotive and commercial finance company and concurrently as Executive Vice President – Chief Financial Officer and Chief Operating Officer of NYSE listed Westcorp, Inc, an OTS regulated bank. He was responsible for operations and all financial areas including SEC filings, analyst interaction, earnings calls, and treasury of both companies. Mr Costantino played a key role in the negotiation and ultimate sale of both companies to Wachovia (Wells Fargo) for $3.9 billion. Prior to that, he was President & CEO and member of the Board of Directors of Mitsubishi Motors Credit of America, Inc – an automotive finance company with over $10 billion in assets, where he is credited with one of the greatest turnarounds in captive finance industry history taking the company from extreme financial losses to profitability and ultimately negotiating the sale of the company’s assets to Merrill Lynch. Prior to that, he served for 17 yrs at various escalating management positions of Volvo Cars of North America including the unique experience of being SVP & CFO of both the automotive parent company and the captive finance company. He was integral to the successful relocation of the company from the East Coast to CA, as part of the creation of the Premier Auto Group after Ford Motor Company acquired Volvo. Mr Costantino’s long successful experiences in many senior executive positions, CPA, public company experience and finance background including executing billions of dollars of asset backed security transactions, as well as multi-billion dollar asset and entire company sales are material factors regarding his qualifications to serve on our Board of Directors.
“I am extremely excited to be joining such an innovative company with disruptive technology in the animal health market and beyond at this pivotal moment in its history.” said Rob Costantino. “With each of my meetings with management and members of the Board of Directors, I became more convinced that PetVivo is ready to launch to new heights and believe I can make valuable contributions on their Board. I am absolutely thrilled to be appointed to the PetVivo Board of Directors and can’t wait to get to work with these visionary company leaders.”
Ms. Coolidge served as a director of Power Solutions International, Inc. where she chaired that company’s Audit Committee. She retired as an Audit and SEC Reviewing Partner from KPMG LLP. At KPMG, Ms. Coolidge led significant global audit engagements, serving major companies with their complex accounting, financial and strategic needs. During her 28 years at KPMG, Ms. Coolidge led client engagement teams auditing SEC registrants and concurrently served as concurring reviewing partner. In addition to her client engagements, she served as a partner in KPMG’s Department of Professional Practice as well as the firm’s representative on the American Institute of CPAs’ (“AICPA”) Accounting Standards Executive Committee. Ms. Coolidge serves on the Board of the Chicago Academy of Sciences and its Peggy Notebaert Nature Museum. Ms. Coolidge holds a Bachelor of Arts degree in Government from Harvard University and a Master of Science degree in Accounting from New York University. Ms. Coolidge qualifies as an “Audit Committee Financial Expert” under applicable SEC regulations and has substantial public company audit experience gained from her tenure as a partner at KPMG. Ms. Coolidge brings to the Board a wealth of experience and knowledge of public company financial reporting and accounting and her experience at the highest levels of a Big Four accounting firm is an invaluable resource to the Board in its oversight of the Company’s financial statements and SEC filings.
“I’ve always believed that technology has the potential to create a better quality of life for people and animals,” said Leslie Coolidge. “It’s an honor to be part of a technology company introducing an innovative medical device that addresses the cause of an affliction, rather than simply treating the symptoms.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG ™ with OsteoCushion ™ technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.
PetVivo Holdings Inc. (PETV:NASDAQ) is a small, and on the outside, unassuming biomedical device company based in Minnesota. Yet, its CEO John Lai is not the typical prototype executive you would expect to be running a biomedical company. John had a successful career on Wall Street, identifying companies with good products or services that held massive opportunities for a better-than-average return on investment. His unique skillset led John to start his own firm, where he was introduced to the PetVivo story.
After his due diligence, Lai recognized that PetVivo’s all-natural products could provide comfort to millions of pets suffering from osteoarthritis. It had the science, patent protection, and a huge addressable market. It all looked well and good, so John decided to join PetVivo and take the company.
Two Setbacks on the Path to Success
However, this did not come without its setbacks. After a series of unfortunate circumstances—including a four-year audit involving the medical device company that PetVivo merged with to become a publicly-traded company—the stock price suffered, leading to a series of reverse splits.
PetVivo has been on a rough road, and the company has faced some significant challenges. Under Lai’s leadership and his and his team’s passion, I would suggest that the company has positioned itself to excel in the months and years to come.
Still, Lai and PetVivo did not give in and leave with their tails between their legs. Instead, they took an unexpected turn in the right direction. John used his background in the capital markets and did not allow the company to do any death spiral financings. John, and a few believers in his abilities and PetVivo’s value proposition, stepped up and made an awe-inspiring move to support the company and get through the tough times without blowing up the cap table. In the end, PetVivo completed the lengthy process of a four-year audit without any material changes occurring.
PetVivo’s executive team focused on building up their manufacturing capabilities to bring them in line with the projected demand. It also helps that PetVivo is not reliant upon foreign entities for its products. There are no supply chain issues to be concerned over. All its manufacturing needs can be met and expanded with a minimal cap-ex spend at its facility in Minneapolis, Minnesota. The PetVivo ISO certified clean room facility currently has the capacity for 500k doses annually.
Yet, on its road to success, PetVivo had to face another hurdle. Covid-19 struck in 2020, causing another setback that impacted the progress of achieving scale and significant sales growth. Due to quarantine, PetVivo was limited in its ability to meet with veterinarians to educate them on these new Osteoarthritis solutions.
Why PetVivo?
While they had to overcome many difficulties, PetVivo has a plethora of benefits that aid in its upward mobility. For one, PetVivo’s “Spryng with OsteoCushion” product has been given to hundreds of horses and dogs through a single injection to treat joint pain due to the loss of cartilage. What makes the product extremely compelling is that it is an all-natural solution. According to their website, “Spryng is a comprised of two naturally derived proteins (collagen and elastin) and one carbohydrate.”
Osteoarthritis affects approximately 14 million adult dogs and 1 million horses. It causes pain and inflammation from degenerated cartilage of stressed joints. Eventually, lameness worsens from the ongoing loss of cartilage and the inflammation present in the joint. While there are medications to manage this, the current solutions treat the symptoms rather than manage the cause.
The Optimal Osteoarthritis (OA) Solution: Spryng With OsteoCushion Technology
Spryng provides a biocompatible lubricious cushion, which reinforces the cartilage barrier between the bones to protect the remaining cartilage and bone and improve joint function. It does this by using similar components/functions found in natural cartilage (i.e., collagen, elastin, and heparin). Spryng particles are injected into the synovial space with standard intra-articular injection technique; multiple joints can be injected simultaneously.
Case studies indicate long-lasting (e.g. ~12 months or longer) improvement in lameness. Spryng also avoids NSAIDs side effects by minimizing their use, making it an effective and economical solution for managing OA.
The anecdotal evidence that Spryng has received has been overwhelmingly positive compared to the other potential solutions on the market today. However, to effectively get the veterinarians to prescribe Spryng, PetVivo needs more than anecdotal evidence; they need to conduct animal studies with documented results. Covid-19 played a role in delaying the data to be provided from the animal studies as well as making it more difficult to speak with veterinarians about this solution.
These setbacks are discouraging for investors that have been involved since the beginning. Still, I don’t suggest we fret yet. The good news is that with Covid-19 no longer being a severe enough issue to shut down the economy, businesses are getting back to a more normalized work environment, and Lai refused to spend the downtime sitting around.
During the halt, Lai managed to assemble an all-star team of executives to help execute his vision for the company. The level of talent that has decided to join the company would not be jumping on board unless there was something they felt has the real promise of success in the portfolio.
Potential Catalysts on the Horizon
Statistically significant results should be presented within the next two quarters with the independent animal studies back on track. Those results will help validate PetVivo’s Spryng therapy, priced at a much lower cost to the consumer than today’s alternative treatments. There is potential for new distribution partnerships and pet insurance coverage as well. A much larger pet care company could also be interested in acquiring PetVivo at the current depressed price levels.
The Spryng treatment, because of its natural ingredients, could open up a whole new way of potentially preventing the onset of Osteoarthritis by performing the injection ahead of complete deterioration of the cartilage, especially for horses and large-breed dogs.
PetVivo has been on a rough road, and the company has faced some significant challenges. Under Lai’s leadership and his and his team’s passion, I would suggest that the company has positioned itself to excel in the months and years to come.
Technically, the stock price seems to have found significant support in the $1.25 area. There will likely be resistance in the two dollars and $2.50 areas. The big area to take out would be the $3.00 range. If the share price were able to close above that level, I could easily see a run to $5.00 on any meaningful fundamental news. If the share price were to close below $1.25, it could see a flush below $1.00.
However, without any significant fundamental news to justify that drop, I would view that as an opportunity to get aggressive in building my position. With just around 10 million shares outstanding and around 6 million in the float, insider support/participation, and no debt. I believe the risk-reward is favorable at these levels.
For more information, click the link to watch my full interview with PetVivo CEO John Lai.
Corp Interview
New to The Street TV welcomes Mr. Mark Middleton, National Sales Director at PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW), for his interview with TV Host Jane King. PetVivo Holdings, Inc. is a biomedical device company that focuses on manufacturing, commercialization, and licensing innovative medical devices and therapeutics for companion animals. As PETV’s National Sales Director , Mark talks about his history within the pet products industry, dealing with FDA manufacturing, product distributions, capital markets, and mergers/acquisitions. He sees himself as a perfect fit at PETV; he understands the veterinarians (DVMs) needs for best practices and product result outcomes for their clients’ animals. The injectable patented Spryng with OsteoCushion Technology treats osteoarthritis and joint afflictions while providing rehabilitation treatments for horses and dogs and continues to grow as a reliable DVM treatment. Being an entirely naturally derived product, Spryng is superior to competitors’ non-biological, synthetic products, and the Spryng treatment lasts longer. The PETV has a talent team who understands science, finance, sales/marketing, manufacturing, distribution, etc. With patience, persistence, and follow-through, Mark sees a strong future for PETV. The on-screen QR code is available during the show; download or visit PetVivo Holdings, Inc. – https://petvivo.com/ and Spryng with OsteoCushion Technology – https://www.sprynghealth.com/ .
About PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW):
PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies to treat companion animals in a capital and time-efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices that enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a pipeline of seventeen products to treat animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes, and use methods. The Company’s lead product Spryng with OsteoCushion Technology , a veterinarian-administered, intraarticular injection to treat lameness and other joint-related affliction, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians – https://petvivo.com/ & https://www.sprynghealth.com/ .
Neither PSN or WSR nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is not a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN or WSR website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN or WSR website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN or WSR website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.. All Reports are reviewed for accuracy and concur that any conclusions made are reasonable expectations. The term Buy List referring to a Watch List and not a recommendation to buy . Each individual has their own risk level and should know their risk level and act accordingly